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Abstract Fabry disease is a monogenic X-linked lysosomal
storage disease caused by α-galactosidase A (αGalA) defi-
ciency. Enzyme replacement therapy through administration
of the missing αGalA is currently the only accepted therapeu-
tic option. However, this treatment is connected to high costs,
has ill-defined indication criteria and its efficacy is controver-
sially discussed. Our aim was to explore the possibility of a
novel targeted substrate reduction therapy for Fabry disease.
Owing to the fact that αGalA-deficient humans and mice
accumulate the same glycosphingolipids (i.e. globosides,
galabiosylceramide and isoglobosides),αGalA-deficient mice
were crossed with mice deficient in enzymes synthesiz-
ing these c lasses of g lycosph ingo l ip ids ( i . e .
globotrihexosylceramide and isoglobotrihexosylceramide
synthase, respectively). Functional heart and kidney tests
were performed together with an extensive biochemical
analysis of urine and serum in aged mice. Lysosomal
storage was assessed by thin layer chromatography and
electron microscopy. We showed that depletion of
globosides was sufficient to fully abolish the storage
of glycosphingolipids in heart, kidney and liver and
was paralleled by a complete restoration of lysosomal
morphology in these organs. In contrast, in dorsal root
gang l i a , a dep le t ion of bo th g lobos ides and
isoglobosides was necessary to fully counteract the ly-
sosomal storage. The deficiency in globosides and/or
isoglobosides did not cause any adverse effects. We
conclude that substrate reduction therapy through inhi-
bition of the synthesis of globosides and isoglobosides
represents a valuable therapeutic option for Fabry dis-
ease, all the more as globosides and isoglobosides seem
to be dispensable.
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Introduction
Fabry disease (Angiokeratoma corporis diffusum, OMIM
301500) was simultaneously described in 1898 by the German
dermatologist Johannes Fabry and the British surgeon Wil-
liam Anderson (Fabry 1898; Anderson 1898). It is a monoge-
netic X-linked disorder characterized by different mutations of
the α-galactosidase A (αGalA) gene including deletions,
missense/nonsense, and frame-shift mutations or splice site
defects (Brady et al. 1967; Topaloglu et al. 1999; Auray-Blais
et al. 2008). The resulting decreased or absent activity of the
enzyme αGalA leads to lysosomal accumulation of
glycosphingolipids (GSL), the most prominent of them being
globotrihexosylceramide (Gb3; Fig. 1) (Sweeley and
Klionsky 1963; Hozumi et al. 1990).
Fabry disease is one of the most frequent storage disorders.
The incidence of the classical phenotype is estimated as
1:40,000. Recent studies, also including late-onset (non-
classical) phenotypes, have reported an incidence between
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1:3,100 to 1:4,600 newborns (Spada et al. 2006; Hwu
et al. 2009). Random inactivation of one of the X-
chromosomes in females and mutations with partially
preserved enzyme activity lead to atypical or attenuated
disease manifestations.
In male patients with the classical phenotype, clinical
symptoms usually begin in childhood and include charac-
teristic skin lesions (angiokeratomas), acroparesthesias, cor-
neal opacity, and hypohidrosis. The kidney involvement
manifests as proteinuria and declining kidney function
which inevitably progresses to end-stage kidney disease.
Cardiac manifestations include left ventricular hypertrophy,
conduction abnormalities, and coronary artery disease with
ensuing congestive heart failure, arrhythmias, and myocar-
dial infarction, respectively. Transient ischemic attacks,
early strokes, white matter lesions, vertigo, and hearing
loss belong to further prominent, however unspecific,
symptoms (reviewed in Desnick et al. 2003; Clarke 2007;
Schiffmann 2009).
Currently, the only accepted treatment for Fabry disease is
enzyme replacement therapy (ERT) with one of the two prep-
arations: Agalsidase-alfa (Replagal®; Shire HGT) or
agalsidase-beta (Fabrazyme®; Genzyme) (Brady 2006;
Schiffmann 2009).
Although ERT is generally well tolerated and has been
shown to reduce the tissue and plasma Gb3 concentration in
Fabry patients, no consistent evidence of clinical efficacy
could be provided (Sheppard et al. 2010; Pisani et al. 2012;
Rombach et al. 2013a; El Dib et al. 2013; Tøndel et al. 2013).
Due to the low prevalence of the disease and variable defini-
tions of end-points in the available studies, therapy indications
are still ill-defined—a non-negligible aspect with regard to the
substantial costs of the aforementioned ERT drugs (Rombach
et al. 2013b). Moreover, ERT is linked to several problems
such as insufficient tissue availability (e.g., due to the blood–
brain barrier) or formation of antibodies against αGalAwhich
may have neutralizing effects or lead to infusion-associated
reactions (Ohashi et al. 2008; Deegan 2012; Rombach et al.
2012; Wilcox et al. 2012).
As a monogenic disorder, Fabry disease might also be
amenable to gene therapy. Although this approach has been
repeatedly tested inmice, the achievement of a safe delivery of
the nucleic acid to all target cells and a sustained expression of
the enzyme are still the major hurdles of such therapy in
humans (Jung et al. 2001; Przybylska et al. 2004;
Yoshimitsu et al. 2006; Choi et al. 2010).
A different approach in the treatment of storage disor-
ders is represented by substrate reduction therapy (SRT). In
contrast to Fabry patients, individuals with Gaucher disease
suffer from lysosomal storage of all GlcCer-derived GSL
(Fig. 1). For the treatment of Gaucher patients, an SRT has
been established and is based on the inhibition of GlcCer
synthase (GCS) (Zimran 2011). This approach is also being
considered for Fabry disease (Abe et al. 2000; Platt et al.
2003; Marshall et al. 2010). However, GCS inhibition
depletes more GSL groups than would be needed to inter-
fere with the storage caused by αGalA deficiency in Fabry
patients (Fig. 1). As GlcCer-derived GSL play an indis-
pensable role in numerous biological processes such as
embryogenesis, central and peripheral nervous function,
or epidermal skin barrier (Jennemann and Gröne 2013),
their depletion may under certain circumstances be
Fig. 1 Glycosphingolipid metabolism. Relevant glycosphingolipids are
depicted together with the corresponding synthesis (black) and degra-
dation (red) enzymes. Depending on the first hexose moiety added to
ceramide (Cer) , e i ther galactosylceramide (GalCer) or
glucosylceramide (GlcCer) is formed. GlcCer is further processed to
lactosylceramide (LacCer, i.e. GalGlcCer). Through the action of
further enzymes on GalCer or LacCer, individual groups of GSL are
produced, from which only the first member is shown for the sake of
clarity. Globotrihexosylceramide synthase (Gb3S) is responsible for the
synthesis of Gb3 and galabiosylceramide (Gal2Cer, i.e. GalGalCer).
Isoglobotrihexosylceramide synthase (iGb3S) synthesizes iGb3. α-
Galactosidase A (αGalA), which catalyzes the degradation of Gb3,
iGb3 and Gal2Cer, is deficient in Fabry disease. In contrast, patients
with Gaucher disease suffer from GSL accumulation due to a defi-
ciency in acid β-glucosidase (βGC). GCS glucosylceramide synthase;
GlcNAc N-acetyl glucosamine; NANA N-acetylneuraminic acid; S
sulfate
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accompanied by adverse effects (Hollak et al. 2009;Machaczka
et al. 2012).
We hypothesized that, for Fabry disease, an SRT by
a targeted depletion of globosides and/or isoglobosides
would suffice to counteract the lysosomal storage phe-
notype without affecting the synthesis of other GlcCer-
based GSL and thus potentially lead to fewer side-
effects. Our results demonstrate in vivo that interfering
with the synthesis of globosides and isoglobosides fully
reverted the Fabry phenotype. Therefore, an SRT by inhibition
of enzymes synthesizing globosides and isoglobosides repre-
sents a valuable therapeutic option for Fabry disease and
should be considered in future research.
Materials and methods
Mice
Mice deficient for Gb3S (EC 2.4.1.228, A4galttm1.1Poru) and
iGb3S (EC 2.4.1.87, A3galt2tm1.1Hjg) were generated by our
group and backcrossed for more than 10 generations to the
C57BL/6 genetic background (Porubsky et al. 2007, 2012).
Mice deficient for αGalA (EC 3.2.1.22, Glatm1Kul) were pro-
vided by Ashok Kulkarni (Ohshima et al. 1997). All strains
were housed under specific pathogen-free conditions and kept
under a 12/12 h light/dark cycle with access to water and
regular chow ad libitum.
Urine was collected using metabolic cages with water
access ad libitum. Analysis of plasma and urine samples
was performed on an Hitachi 9-17E analyser (Hitachi,
Frankfurt, Germany). Creatinine clearance was calculated
as UCrxV24/(PCrx24x60), where UCr and PCr are creatinine
concentrations in urine and plasma, respectively, and V24 is
the 24-h urine volume. Peripheral blood, spleen, and thymus
were analyzed by flow cytometry as detailed in Porubsky
et al. (2007, 2012).
Transthoracic echocardiography
Non-invasive transthoracic echocardiography was performed
in a modified setting as previously described (Malekar et al.
2010). In brief, a two-dimensional parasternal short axis view
andM-mode tracings of the left ventricle were obtained with a
Sonos 5500 echocardiogram (Philips, Andover, MA, USA)
using a S12 transducer (12MHz). M-mode tracings were used
to measure left ventricular internal diameter (LVID) as the
largest anteroposterior diameter in either diastole (LVIDd) or
systole (LVIDs) and averaged from at least three consecutive
cardiac cycles. Left ventricular fractional shortening was cal-
culated as (LVIDd-LVIDs)/LVIDd and expressed as a percent-
age. The heart rate was calculated based on the M-mode
tracings.
Isolation and analysis of GSL
Freshly harvested organs were frozen in liquid nitrogen and
lyophilized. Tissues were powdered and dry weight was de-
termined. Extraction of GSL from organs and the subsequent
analysis by thin layer chromatography (TLC) were performed
as described in detail in Porubsky et al. (2012); briefly, GSL
were eluted from organs using CHCl3/CH3OH/H2O. In order
to eliminate phospholipids and triglycerides, crude extracts
were treated with 1 ml 0.1MKOH in CH3OH at 50 °C for 4 h.
After neutralization with acetic acid and evaporation of
CH3OH, potassium acetate was removed from lipids via re-
versed phase column chromatography (RP18). Neutral and
acidic (sialic acid-containing) GSL were separated by ion
exchange chromatography.
For TLC, an amount corresponding to 2 mg dry organ
weight was loaded. Running solvent was CHCl3/CH3OH/
H2O (62.5:30:6, v/v/v) for neutral GSL and CHCl3/CH3OH/
0.2% CaCl2 in H2O (60:35:8, v/v/v) for acidic GSL. To
visualize GSL, the TLC plate was sprayed with 0.2 % orcinol
in 10 % sulfuric acid and incubated 10 min at 120 °C.
Histology and immunohistochemistry
Tissue samples were fixed in 4 % phosphate buffered formal-
dehyde, paraffin-embedded, and cut at 4 μm. The cuts were
subjected to routine staining procedures including hematoxy-
lin and eosin stain (HE), periodic acid-Schiff (PAS), and
Goldner stain. For Gb3-immunohistochemistry, cryosec-
tions were fixed with formaldehyde and probed with
polyclonal chicken anti-Gb3 antibody JM06/298-1
(Betz et al. 2011) followed by alkaline phosphatase-
conjugated polyclonal donkey anti-IgY secondary anti-
body (Jackson ImmunoResearch Europe, Suffolk, UK).
Slides were scanned by Mirax Scan (Carl Zeiss, Ger-
many). Pictures were exported using the Panoramic
Viewer (3DHISTECH, Budapest, Hungary).
Electron microscopy
Organs were fixed in Karnovsky’s glutaraldehyde (2 % para-
formaldehyde, 2.5 % glutaraldehyde, 0.2 M cacodylate buffer
pH 7.4) and embedded in araldite (Serva, Heidelberg, Germa-
ny). Ultrathin sections were stained with lead citrate and
uranyl acetate. Photographs were taken on an electron
microscope (EM 910; Carl Zeiss).
Statistical analysis
Unpaired two-tailed Student’s t test was performed to compare
datasets. Differences were considered significant if p<0.05.
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Results
Characterization of the gene deficient mice strains
Although αGalA-deficient mice accumulate the same GSL as
humans, only a weak or non-functional organ impairment has
been previously reported in αGalA-deficient mice (Ohshima
et al. 1999; Yoshimitsu et al. 2006; Noben-Trauth et al. 2007;
Marshall et al. 2010). Because all mice strains described in
this study were backcrossed for more than 10 generations to
the C57BL/6 genetic background and were strictly kept under
identical conditions, we first sought to test whether, under
these circumstances, any functional alterations would be de-
tectable in αGalA-deficient mice in comparison to WT mice.
Transthoracic echocardiography did not reveal any signif-
icant difference of the left-ventricular end-diastolic diameter
(LVEDD), left-ventricular end-systolic diameter (LVESD),
left ventricular fractional shortening (LVFS), and ejection
fraction in aged (1.5-year-old) αGalA-deficient mice as com-
pared toWTmice (Fig. 2a–d). Similarly, the heart rate was not
altered in αGalA-deficient mice (Fig. 2e). Assessment of the
kidney function using metabolic cages did not show any
significant changes in creatinine clearance, urine volume,
proteinuria, and albuminuria in αGalA-deficient mice in com-
parison to WT mice (Fig. 2f–i).
As further detailed in the Table 1,αGalA deficiency did not
impact body and organ weights; the only exception being the
kidney weight which was significantly increased in αGalA−/−
females as compared to WT, αGalA−/−/Gb3S−/−, and Gb3S−/
− female mice. Similarly, among all biochemical parameters
tested in serum and urine, an increased cholesterol level could
only be observed in αGalA–/0 male mice as compared to WT,
αGalA–/0/Gb3S−/−, and Gb3S−/− male mice (Table 1).
Mice with deficiency for globotrihexosylceramide syn-
thase (Gb3S) and isoglobotrihexosylceramide synthase
(iGb3S) have been previously reported, and the deficiency in
globosides and/or isoglobosides did not impact either organ
histology or any physiological function so far tested
(Electronic Supplementary Material, Fig. S1; Porubsky et al.
2007, 2012).
Due to the absence of a functional organ impairment
in αGalA-deficient mice with a pure genetic background,
we based all further investigations on biochemical and
ultrastructural analyses.
Biochemical analysis of GSL stored in αGalA-deficient mice
In αGalA-deficient humans and mice, Gb3 has been implicat-
ed as the most prominent GSL stored (Fig. 1). In order to test
this in a genetic approach,αGalA-deficient mice were crossed
withGb3S−/−mice (αGalA−/−/Gb3S−/−) and tissue GSL were
extracted. The analysis was focused on kidney, liver, and heart
as these organs have been previously shown to have a prom-
inent GSL accumulation in humans and mice (Hozumi et al.
1990; Ohshima et al. 1999).
Fig. 2 Functional analysis of the heart and kidney. In aged (1.5-year-old)
αGalA−/− female mice, heart and kidney function were measured. a–e
The heart function was tested using transthoracic echocardiography. No
significant difference of the left-ventricular end-diastolic diameter
(LVEDD, a), left-ventricular end-systolic diameter (LVESD, b), left
ventricular fractional shortening (c) and ejection fraction (d) could be
observed betweenαGalA−/− andWTmice. Similarly, no difference in the
heart rate could be demonstrated between αGalA-deficient and WT mice
(e). Bars represent means, and whiskers standard deviations, n=5 and 8
for WT and αGalA−/− mice, respectively. f–i The kidney function was
tested based on serum creatinine and analysis of 24-h urine. No differ-
ences in the creatinine clearance (f), urine volume (g), proteinuria (h), and
albuminuria (i) could be demonstrated between αGalA−/− and WT mice.
Bars represent means, and whiskers standard deviations, n=9
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TLC analysis of neutral GSL extracted from αGalA-
deficient mice showed that, in kidney, liver, and heart, the
most prominent accumulating GSL ran at the height of Gb3
(Fig. 3a–c). In addition, in kidneys of αGal-deficient mice,
galabiosylceramide, another product of Gb3S, accumulated.
In the αGalA−/−/Gb3S−/− double knockout-mice, the defi-
ciency in Gb3S could fully abolish the GSL accumulation as
detected by TLC (Fig. 3a–c). As a consequence of the Gb3S
Table 1 Anatomical and biochemical parameters
Females WT αGalA−/− αGalA−/−/Gb3S−/− Gb3S−/−
Body weight (g) 25.8±4.1 25.9±2.2 27.4±3.2 26.8±3.3
Lungs (g) 0.160±0.030 0.171±0.024 0.161±0.014 0.156±0.014
Heart (g) 0.164±0.026 0.176±0.017 0.176±0.018 0.184±0.036
Liver (g) 1.203±0.153 1.496±0.455 1.312±0.131 1.229±0.182
Spleen (g) 0.120±0.032 0.129±0.051 0.111±0.030 0.096±0.035
Kidneys (g) 0.287±0.031 0.331±0.028 * 0.305±0.024 0.283±0.032
S-Creatinine (mg/dl) 0.11±0.05 0.10±0.02 0.09±0.01 0.09±0.01
S-Urea (mg/dl) 41.8±17.5 47.6±10.8 51.7±15.1 50.4±10.4
S-Protein (mg/ml) 59.3±10.2 52.6±7.8 55.8±5.8 54.1±2.6
S-Glucose (mg/dl) 128.8±25.8 124.5±23.3 110.6±15.4 116.2±22.5
S-Cholesterol (mg/dl) 98.7±14.3 95.4±11.1 101.5±17.7 89.1±12.6
S-TAG (mg/dl) 74.2±18.5 81.0±14.2 68.1±16.3 67.1±16.6
U-Creatinine (mg/dl) 31.9±11.3 33.8±12.7 28.8±12.9 37.7±23.7
U-Urea (mg/dl) 3,738±1,411 5,290±2,167 3,903±1,516 5,419±2,788
U-Glucose (mg/dl) 8.00±8.44 13.67±7.60 9.80±9.61 15.43±13.94
U-Na+ (mmol/l) 66.3±60.1 95.1±58.0 59.3±34.2 73.3±44.2
U-K+ (mmol/l) 137.3±92.3 176.8±104.5 136.5±71.6 161.5±96.3
U-Ca++ (mmol/l) 3.17±1.82 3.81±1.17 3.12±1.49 2.66±1.53
U-Phosphate (mmol/l) 58.7±20.5 89.7±50.2 65.8±38.3 71.5±47.3
Males WT αGalA−/0 αGalA−/0/Gb3S−/− Gb3S−/−
Body weight (g) 34.0±6.6 37.3±5.0 38.5±4.9 35.6±5.7
Lungs (g) 0.164±0.018 0.170±0.020 0.167±0.019 0.160±0.027
Heart (g) 0.223±0.038 0.205±0.039 0.244±0.054 0.231±0.045
Liver (g) 1.724±0.379 1.532±0.230 1.567±0.309 1.494±0.224
Spleen (g) 0.094±0.058 0.094±0.015 0.082±0.023 0.080±0.039
Kidneys (g) 0.400±0.085 0.396±0.035 0.366±0.033 0.372±0.045
S-Creatinine (mg/dl) 0.14±0.23 0.09±0.02 0.10±0.02 0.09±0.02
S-Urea (mg/dl) 50.5±14.6 46.3±7.4 56.3±22.0 60.2±24.6
S-Protein (mg/ml) 58.1±5.7 59.2±4.5 61.1±7.2 59.8±5.8
S-Glucose (mg/dl) 125.4±62.0 143.9±56.9 120.3±39.6 99.0±27.4
S-Cholesterol (mg/dl) 116.8±26.6 167.9±27.1 # 123.6±22.3 113.1±16.2
S-TAG (mg/dl) 96.1±25.3 105.7±18.1 89.9±26.6 92.9±31.7
U-Creatinine (mg/dl) 33.1±12.1 34.2±21.2 23.9±9.5 31.6±10.9
U-Urea (mg/dl) 6,068±2,803 4,632±1,677 3,3662±1,318 4,161±992
U-Glucose (mg/dl) 18.64±23.20 13.40±8.95 6.91±8.61 13.77±8.11
U-Na+ (mmol/l) 125.3±103.2 90.2±45.3 81.0±34.8 90.5±51.5
U-K+ (mmol/l) 182.9±125.5 132.8±54.1 144.4±62.7 135.6±54.3
U-Ca++ (mmol/l) 2.65±1.75 3.69±2.11 2.56±0.83 3.49±2.06
U-Phosphate (mmol/l) 90.5±52.0 68.6±30.4 60.3±27.1 58.1±23.4
*αGalA−/− females had a significantly higher (p<0.05) kidney weight than WT, αGalA−/− /Gb3S−/− and Gb3S−/− females
#αGalA–/0 males had significantly higher (p<0.001) serum cholesterol levels than WT, αGalA–/0 /Gb3S−/− and Gb3S−/− males
S serum; TAG triacylglycerol; U urine
Values represent mean±SD; n=9-13 mice per group
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deficiency, a slight increase in its substrate LacCer could be
seen in kidneys ofαGalA−/−/Gb3S−/−mice (Fig. 3a–c). How-
ever, this did not led to any compensatory increase in other
LacCer-derived GSL (Figs. 1, 3). No accumulation of acidic
GSL occurred in αGalA-deficient mice (Fig. 3d–f).
Impact of Gb3S deficiency on the storage phenotype
in αGalA-deficient mice
To corroborate the TLC findings with histology, immunohis-
tochemistry with anti-Gb3 antibodies was performed on kid-
ney and liver tissue. In WT kidneys, a strong Gb3 expression
could be observed in collecting ducts (Fig. 4a). In αGalA-
deficient mice, the Gb3 synthesis became apparent due to the
absence of its catabolism also in other nephron segments
(Fig. 4b). In contrast, glomerular cells stained negative for
Gb3 in WT mice as well as in αGalA-deficient mice (data not
shown). In congruence with the TLC analysis, livers showed
no Gb3 expression upon immunohistochemical investigation
in WT mice but its accumulation was present in αGalA-
deficient animals (Fig. 4d, e). Gb3S deficiency abolished the
accumulation of globosides observed in organs of αGalA-
deficient mice (Fig. 4c, f).
Furthermore, organs were subjected to ultrastructural
analysis, which represents the decisive method for visu-
alization of lysosomal storage phenomena. In αGalA-
deficient mice, the storage could be documented as
concentric and lamellar lysosomal inclusions (Fig. 5b,
e, h) which are also characteristic for the human dis-
ease. In line with the immunohistochemical findings, an
extensive accumulation could be documented in renal
tubular epithelial cells in αGalA-deficient mice
(Fig. 5b, e). In contrast, podocytes and renal endothelial
cells of αGalA-deficient mice showed a regular ultra-
structure. Singular podocytes alone showed a slight ly-
sosomal enlargement and lamellar structures resembling
αGalA deficiency (data not shown).
Electron microscopy revealed the lysosomal storage also in
Kupffer and Ito cells in livers of αGalA-deficient mice
(Fig. 5h). In hearts of αGalA-deficient mice, endothelial and
interstitial cells were affected by the storage (Electronic Sup-
plementary Material, Fig. S2).
In αGalA− /−/Gb3S−/− mice, the elimination of
globosides restored a normal lysosomal morphology in
kidney, liver and heart and resulted in an ultrastructural
appearance indistinguishable from WT mice (Fig. 5c, f,
Fig. 3 Analysis of GSL from
selected organs. Neutral (a–c) and
acidic (d–f) GSL extracted from
kidneys, livers, and hearts of WT,
αGalA−/−, andαGalA−/−/Gb3S−/−
mice were analyzed by TLC. In all
three organs, αGalA deficiency
resulted in accumulation of a
neutral GSL which ran at the
height of Gb3 and was absent in
the αGalA−/−/Gb3S−/− double
knockout thus confirming its
identity as Gb3 (a–c).
Accumulation of
galabiosylceramide (Gal2Cer)
contributed to the storage in
kidneys of αGalA−/−mice (a), but
was—in agreement with being a
product of Gb3S—absent in
αGalA−/−/Gb3S−/− kidneys. Gb3S
deficiency resulted in a slight
accumulation of its substrate
lactosylceramide (LacCer) in
kidneys (a). Among the acidic
GSL (d—f), no accumulation was
observed in αGalA−/−mice. Some
GSL are represented by multiple
bands due to their heterogeneous
composition of fatty acids resulting
in different running properties.
Orcinol staining. Std. GSL
standard
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i; Electronic Supplementary Material, Fig. S2). Thus,
Gb3S deficiency was sufficient to abolish the lysosomal
storage associated with αGalA deficiency in these or-
gans, yet without causing any developmental or histo-
logical abnormalities and without interfering with organ
function (Table 1 and Porubsky et al. 2007, 2012).
Contribution of isoglobosides to the storage phenotype
in dorsal root ganglia
A comprehensive ultrastructural analysis of other struc-
tures revealed that—in contrast to the previously men-
tioned organs—in dorsal root ganglia (DRG) of
αGalA−/−/Gb3S−/− mice, a lysosomal storage was still
present (Fig. 6). Taking into account that iGb3 is syn-
thesized in DRG (Speak et al. 2007), we analyzed DRG
of αGalA−/−/iGb3S−/− mice. However, the sole deficien-
cy in iGb3S did not suffice to counteract the storage
phenotype associated with αGalA deficiency in DRG.
Only a simultaneous depletion of both globosides and
isoglobosides (i.e. in the αGalA−/−/Gb3−/−/iGb3−/−
mouse) was able to abolish the lysosomal storage and
restore a normal ultrastructural morphology in the DRG
(Fig. 6h, j).
Discussion
These results demonstrate that, inαGalA deficiency, depletion
of globosides was sufficient to fully revert the storage pheno-
type in the most prominently affected organs like heart, liver,
and kidney (Figs. 3, 4, 5, 6). To achieve a complete restoration
of the lysosomal morphology in DRG, which also produce
isoglobosides, the simultaneous depletion of both globosides
and isoglobosides was necessary (Fig. 6). The latter finding is
supported by a previous investigation, which documented the
synthesis of iGb3 only in the DRG but not in other murine
organs (Speak et al. 2007).
The murine model of Fabry disease used in this study
shows—in congruence with the human disease—a complete
lack of lysosomal αGalA activity, which results in an aberrant
lysosomal ultrastructure and function (Ohshima et al. 1997;
Ohashi et al. 2008; Porubsky et al. 2012). However, in con-
trast to Fabry patients, an effect on the function of heart,
kidney, and brain is completely absent or only very mild,
Fig. 4 Immunohistochemical
analysis of the Gb3 storage.
Immunohistochemistry was
performed using Gb3-antibodies
in kidneys (a–c) and livers
(d–f) of WT, αGalA−/−, and
αGalA−/−/Gb3S−/− mice. Gb3
was prominently present in renal
collecting ducts of WT mice but
also emerged in other nephron
segments in αGalA deficiency.
Similarly, in the liver, Gb3 also
accumulated in αGalA−/− mice.
Gb3S deficiency abolished this
storage inαGalA−/−/Gb3S−/−mice.
Scale bars (a–c) 0.5 mm,
(d–f) 0.1 mm
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and the life span is normal in αGalA-deficient mice. In par-
ticular, no ophthalmologic manifestations (Ohshima et al.
1999) and no hearing loss (Noben-Trauth et al. 2007) could
be demonstrated, although some studies have reported slight
sensorimotor alterations (Rodrigues et al. 2009; Marshall et al.
2010) and a marginal myocardial affection (Yoshimitsu et al.
2006; Rozenfeld et al. 2011; Nguyen Dinh Cat et al. 2012).
The latter could not be verified in our colony, possibly due to
the extensive backcrossing towards the reference C57BL/6
strain and a strict breeding of all strains under identical con-
ditions (Fig. 2). Also in line with previous investigations
(Ohshima et al. 1999), we could not detect any decline in
kidney function (measured as creatinine clearance) and no
proteinuria or microalbuminuria in aged αGalA-deficient
mice (Fig. 2). The increased kidney weight in αGalA−/−
females as compared to WT, αGalA−/−/Gb3S−/−, and
Gb3S−/− mice (Table 1) did not show any correlates upon
light microscopy (data not shown). Similarly, the elevated
serum cholesterol in male αGalA–/0 mice (Table 1) was not
reflected by any light microscopic changes in the liver or any
other organ (including heart; data not shown).
The aforementioned absent or very slight functional alter-
ations in the murine model of Fabry disease contrast with the
extensive GSL accumulation and the amply documented de-
rangement of lysosomal morphology in the organs of these
mice (Figs. 3, 4, 5, 6). The paucity of functional correlates in
this mouse model is probably due to the fact that the cells
which determine the organ affection and morbidity in humans
(e.g., podocytes in the kidney or endothelial cells in the heart
and brain) do not express sufficient amounts of Gb3S in mice
and are thus not affected by the storage to an extent which
would allow the development of similar symptoms. This
explanation is supported by a recent report which showed that
αGalA-deficient mice were symptomatic when crossbred
with transgenic mice ubiquitously expressing Gb3S (Taguchi
et al. 2013).αGalA-deficient mice and humans show identical
GSL storage patterns with globosides constituting the vast
majority of the accumulating GSL (Sweeley and Klionsky
1963; Hozumi et al. 1990; Ohshima et al. 1999). Therefore,
although the αGalA-deficient mouse model is not suited for
functional studies, it represents a useful tool to investigate
biochemical and ultrastructural alterations and possible
Fig. 5 Ultrastructural analysis of
selected organs. Organs of
WT, αGalA−/−, and
αGalA−/−/Gb3S−/− mice
were analyzed by electron
microscopy for the presence
of ultrastructural correlates
of a lysosomal storage disease.
a–f In kidneys of αGalA−/−mice,
numerous enlarged lysosomes
with characteristic concentric
lamellar inclusions were present
in tubular epithelial cells
(black arrow). Depletion of
globosides fully restored a normal
lysosomal morphology in
αGalA−/−/Gb3S−/− mice. g–i The
storage phenotype in the liver is
exemplified by Ito cells, which
can be identified in the Disse’s
(perisinusoid) space (*endothelial
cells). αGalA deficiency resulted
in a distorted lysosomal
architecture (white arrow) in
αGalA−/− mice but not in the
absence of Gb3S-activity (i.e. in
the αGalA−/−/Gb3S−/− mice).
Stain: lead citrate/uranyl acetate.
Scale bars(a–c) 5 μm, (d–f)
2 μm, (g–i) 0.5 μm
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therapeutic approaches in vivo. In our study, we did not
determine the levels of lyso-Gb3, which has been postulated
as a marker of Fabry disease (Aerts et al. 2008; Togawa et al.
2010), as it can be anticipated that, in the αGalA−/−/Gb3S−/−
mouse, the abolishment of the synthesis of Gb3 will curtail
any production of lyso-Gb3 (Fig. 3).
To date, the only accepted therapy for Fabry disease is
ERT. Besides its high costs and still unproven efficacy, the
most prominent problem of the intravenously administered
enzyme is its bioavailability in target organs. In this regard, an
approach through SRT seems to be advantageous because
tissue availability of small inhibitors can be optimized by
molecular engineering. SRT through inhibition of GCS
(Fig. 1) seems to be possible as a therapeutic option forαGalA
deficiency (Abe et al. 2000; Platt et al. 2003). However, such
an approach also results in depletion of other GSL groups,
which do not contribute to the storage in αGalA deficiency.
Moreover, GSC-inhibition does not interfere with the
Fig. 6 Ultrastructural analysis
of dorsal root ganglia. Dorsal






However, in contrast to
other organs, a restoration
of a normal lysosomal
morphology could not be





also did not lead to a
normalization of the
lysosomal morphology.
This could be achieved only
by a simultaneous depletion of
both globosides and
isoglobosides (i.e. in the
αGalA−/−/Gb3S−/−/iGb3S−/−
mouse). Stain: lead citrate/uranyl
acetate. Scale bars (a–c, g, h)
2 μm, (d–f, i, j) 1 μm
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synthesis of galabiosylceramide in the kidney (Fig. 1) and thus
cannot abolish its accumulation in Fabry disease. Although it
is unclear to which extent the accumulat ion of
galabiosylceramide itself contributes to the renal phenotype
of Fabry disease, inhibition of the Gb3Swould—in contrast to
the inhibition of GCS—eliminate the accumulation not only
of globosides but also of galabiosylceramide.
It could be demonstrated that deficiency in globosides is
protective upon exposure to Shigatoxins (Okuda et al. 2006;
own unpublished data); however, the physiological function
of globosides and isoglobosides remains elusive as no de-
rangements of physiological functions have so far been ob-
served in mice deficient for Gb3S and/or iGb3S (Table 1;
Electronic Supplementary Material, Fig.S1; Porubsky et al.
2007, 2012).
In summary, our study explored the possibility of a targeted
SRT for Fabry disease through the depletion of globosides and
isoglobosides, which both seem to be dispensable for all
biological functions tested so far (Table 1; Porubsky et al.
2007, 2012).We show that interference with the Gb3S activity
abolishes the GSL storage and normalizes lysosomal mor-
phology in most organs. For a complete elimination of storage
phenomena in DRG, isoglobosides have to be depleted in
addition to globosides. We are convinced that a pharmacolog-
ic inhibition of Gb3S and iGb3S represents a potentially
successful SRT for Fabry disease. Experiments are in progress
to identify specific inhibitors of Gb3S and iGb3S.
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